SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases ...
7d
Mutual of America Capital Management LLC trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free ...
We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...
Fintel on MSN9d
Evercore ISI Group Initiates Coverage of SpringWorks Therapeutics (SWTX) with Outperform RecommendationFintel reports that on November 20, 2024, Evercore ISI Group initiated coverage of SpringWorks Therapeutics (NasdaqGS:SWTX) ...
STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer ...
SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biopharmaceutical company focused on developing treatments for rare diseases and cancer, has been making significant strides in its commercial and ...
SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biopharmaceutical company focused on developing treatments for rare diseases and cancer, has been making significant strides in its commercial and ...
Springworks Therapeutics (SWTX – Research Report) received a Buy rating and a $60.00 price target from Evercore ISI analyst Cory Kasimov today.
On Friday, SpringWorks Therapeutics Inc (SWTX) stock saw a decline, ending the day at $36.45 which represents a decrease of $-0.10 or -0.27% from the prior close of $36.55. The stock opened at $36.5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback